ArticleDiscover oncology2026
Retrospective single-center cytohistologic correlation study of fine-needle aspiration cytology for excised superficial enlarged lymph node lesions in different disease entities.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymph nodes are essential components of the human immune system, and lymph node lesions present considerable challenges for pathological diagnosis due to their complexity and heterogeneity. Conventional diagnosis mainly relies on histopathological examination of surgical specimens, whereas fine-needle aspiration cytology (FNAC) of superficial enlarged lymph nodes is a rapid, minimally invasive, and clinically valuable tool for preliminary etiological identification and targeted treatment planning. This study aimed to summarize the cytomorphological features of FNAC in four major categories of superficial enlarged lymph node lesions (lymph node reactive hyperplasia (LNRH), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), and lymph node metastatic carcinoma (LNMC), evaluate the diagnostic efficacy of FNAC using histopathological results as the gold standard, and provide evidence-based references for clinical preliminary diagnosis and treatment decision-making. We retrospectively analyzed 133 consecutive cases of lymph node FNAC followed by surgical resection and histopathological confirmation at a single center from January 2023 to December 2024. FNAC smears were stained with Liu's solution, histopathological sections with hematoxylin and eosin, and immunohistochemistry was applied for disease-specific marker detection. The overall diagnostic accuracy of FNAC was 89.47%. The sensitivity was highest for LNMC (95.52%, 95% CI: 87.23-98.97%), and the specificity was 100.00% for HL (95% CI: 97.19-100.00%). NHL showed a sensitivity of 80.95% and a positive predictive value of 84.00%, while LNRH had a negative predictive value of 90.91%. Chi-square test revealed significant intergroup differences in cellular atypia, cell distribution patterns, and characteristic cells among the four lesion types (P < 0.001). In conclusion, FNAC is a moderately reliable minimally invasive screening tool for superficial enlarged lymph node lesions. Clarifying its diagnostic efficacy and distinct cytomorphological features provides valuable morphological and quantitative evidence for clinicians to conduct preliminary classification and formulate appropriate treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.